Etanercept in erythema nodosum leprosum

Etanercept in erythema nodosum leprosum

Abstract: One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.

Saved in:
Bibliographic Details
Main Authors: Santos,Julia Rocha Silva, Vendramini,Dâmia Leal, Nery,José Augusto da Costa, Avelleira,João Carlos Regazzi
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Dermatologia 2017
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962017000400575
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0365-05962017000400575
record_format ojs
spelling oai:scielo:S0365-059620170004005752017-09-14Etanercept in erythema nodosum leprosumSantos,Julia Rocha SilvaVendramini,Dâmia LealNery,José Augusto da CostaAvelleira,João Carlos Regazzi Leprosy Erythema nodosum Tumor necrosis factor-alpha Abstract: One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.info:eu-repo/semantics/openAccessSociedade Brasileira de DermatologiaAnais Brasileiros de Dermatologia v.92 n.4 20172017-08-01info:eu-repo/semantics/othertext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962017000400575en10.1590/abd1806-4841.20175471
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Santos,Julia Rocha Silva
Vendramini,Dâmia Leal
Nery,José Augusto da Costa
Avelleira,João Carlos Regazzi
spellingShingle Santos,Julia Rocha Silva
Vendramini,Dâmia Leal
Nery,José Augusto da Costa
Avelleira,João Carlos Regazzi
Etanercept in erythema nodosum leprosum
author_facet Santos,Julia Rocha Silva
Vendramini,Dâmia Leal
Nery,José Augusto da Costa
Avelleira,João Carlos Regazzi
author_sort Santos,Julia Rocha Silva
title Etanercept in erythema nodosum leprosum
title_short Etanercept in erythema nodosum leprosum
title_full Etanercept in erythema nodosum leprosum
title_fullStr Etanercept in erythema nodosum leprosum
title_full_unstemmed Etanercept in erythema nodosum leprosum
title_sort etanercept in erythema nodosum leprosum
description Abstract: One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.
publisher Sociedade Brasileira de Dermatologia
publishDate 2017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962017000400575
work_keys_str_mv AT santosjuliarochasilva etanerceptinerythemanodosumleprosum
AT vendraminidamialeal etanerceptinerythemanodosumleprosum
AT neryjoseaugustodacosta etanerceptinerythemanodosumleprosum
AT avelleirajoaocarlosregazzi etanerceptinerythemanodosumleprosum
_version_ 1756412575043551232

Similar Items